Overview and Scope
Migraine drugs refer to medications used to treat a kind of neurological illness in which a person experiences a sharp, throbbing headache. They function by focusing on different physiological mechanisms that cause migraines.
Sizing and Forecast
The migraine drugs market size has grown strongly in recent years. It will grow from $5 billion in 2023 to $5.38 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to advancements in drug formulations, increased awareness and diagnosis, stress and lifestyle factors, expansion of generic drugs, emergence of cgrp inhibitors.
The migraine drugs market size is expected to see strong growth in the next few years. It will grow to $6.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized medicine approaches, telemedicine and remote consultations, healthcare policy and insurance coverage, increasing global migraine burden, combination therapies. Major trends in the forecast period include targeted therapies, telemedicine and remote consultations, patient-centric approaches, digital therapeutics, biosimilars in migraine treatment, clinical research and trials.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/migraine-drugs-global-market-report
Segmentation & Regional Insights
The migraine drugs market covered in this report is segmented –
1) By Drug Class: Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants
2) By Route of Administration: Oral, Injectable, Other Routes
3) By End-User: Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Other End Users
North America was the largest region in the migraine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the migraine drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13484&type=smp
Major Driver Impacting Market Growth
The growing female population is expected to propel the growth of the migraine drugs market going forward. The female population refers to the total number of females in all age groups who are residents in each country or region during a specific period. The prevalence of migraines is significantly higher in the female population compared to males due to a combination of genetic, hormonal, and environmental factors. For instance, in 2022, according to the World Population Prospects 2022 shared by the United Nations, a US-based intergovernmental organization, the population of females in the world is estimated at 4.00 billion, representing 49.75% of the world population, and it is now expected that females will outnumber males by 2049. Therefore, the growing female population is driving the growth of the migraine drugs market.
Key Industry Players
Major companies operating in the migraine drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., AbbVie Inc., Sanofi SA, Novartis AG, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Dr Reddys Laboratories Ltd., H. Lundbeck A/S, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Neurelis Inc., ALDER BIOPHARMACEUTICALS INC., eNeura Inc., Winston Pharmaceuticals Ltd.</b
The migraine drugs market report table of contents includes:
1. Executive Summary
2. Migraine Drugs Market Characteristics
3. Migraine Drugs Market Trends And Strategies
4. Migraine Drugs Market – Macro Economic Scenario
5. Global Migraine Drugs Market Size and Growth
.
.
.
32. Global Migraine Drugs Market Competitive Benchmarking
33. Global Migraine Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Migraine Drugs Market
35. Migraine Drugs Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
